Biblio
Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients. Haematologica. 2023.
. Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma. Blood Cancer J. 2023;13(1):25.
Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma. Methods Mol Biol. 2021;2261:151-191.
.